These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2160535)

  • 1. Conformationally constrained congeners of 6-aryl-5-methyl-4,5-dihydro-3(2H)-pyridazinones active on the cardiovascular system: conformational studies by molecular mechanics calculations and 1H NMR spectroscopy.
    Toma L; Cignarella G; Barlocco D; Ronchetti F
    J Med Chem; 1990 Jun; 33(6):1591-4. PubMed ID: 2160535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-pyridazinyl)- 2H-indol-2-one, a potent inhibitor of cyclic AMP phosphodiesterase.
    Robertson DW; Jones ND; Krushinski JH; Pollock GD; Swartzendruber JK; Hayes JS
    J Med Chem; 1987 Apr; 30(4):623-7. PubMed ID: 3031290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7-(Ethoxycarbonyl)-6,8-dimethyl-2-phenyl-1(2H)-phthalazinone derivatives: synthesis and inhibitory effects on platelet aggregation.
    Sugimoto A; Tanaka H; Eguchi Y; Ito S; Takashima Y; Ishikawa M
    J Med Chem; 1984 Oct; 27(10):1300-5. PubMed ID: 6090662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.
    Sircar I; Steffen RP; Bobowski G; Burke SE; Newton RS; Weishaar RE; Bristol JA; Evans DB
    J Med Chem; 1989 Feb; 32(2):342-50. PubMed ID: 2536438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors.
    Pieretti S; Dominici L; Di Giannuario A; Cesari N; Dal Piaz V
    Life Sci; 2006 Jul; 79(8):791-800. PubMed ID: 16546218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational studies of muscarone analogues: X-ray analysis and molecular mechanics calculations.
    Carroll PJ; De Amici M; De Micheli C; Toma L
    J Med Chem; 1992 Jan; 35(2):305-9. PubMed ID: 1732547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal and molecular structures of pyridazinone cardiovascular agents.
    Prout K; Bannister C; Burns K; Chen M; Warrington BH; Vinter JG
    Acta Crystallogr B; 1994 Feb; 50 ( Pt 1)():71-85. PubMed ID: 8148097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and bioactivity of 6-phenyl-4,5-dihydro-3(2H)-pyridazinone derivatives.
    Wang T; Dong Y; Wang LC; Chen Z
    Arzneimittelforschung; 2007; 57(10):641-6. PubMed ID: 18074757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.
    Van der Mey M; Bommelé KM; Boss H; Hatzelmann A; Van Slingerland M; Sterk GJ; Timmerman H
    J Med Chem; 2003 May; 46(10):2008-16. PubMed ID: 12723963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.
    Giovannoni MP; Cesari N; Graziano A; Vergelli C; Biancalani C; Biagini P; Dal Piaz V
    J Enzyme Inhib Med Chem; 2007 Jun; 22(3):309-18. PubMed ID: 17674813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents.
    Combs DW; Rampulla MS; Bell SC; Klaubert DH; Tobia AJ; Falotico R; Haertlein B; Lakas-Weiss C; Moore JB
    J Med Chem; 1990 Jan; 33(1):380-6. PubMed ID: 2153210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformationally restricted congeners of hypotensive and platelet aggregation inhibitors: 6-aryl-5-methyl-4,5-dihydro-3(2H)-pyridazinones derived from 5H-indeno[1,2-c]pyridazine.
    Cignarella G; Barlocco D; Pinna GA; Loriga M; Tofanetti O; Germini M; Sala F
    J Med Chem; 1986 Nov; 29(11):2191-4. PubMed ID: 3783580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.
    Charifson PS; Bowen JP; Wyrick SD; Hoffman AJ; Cory M; McPhail AT; Mailman RB
    J Med Chem; 1989 Sep; 32(9):2050-8. PubMed ID: 2527994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyridazinone derivatives: design, synthesis, and in vitro vasorelaxant activity.
    Abouzid K; Abdel Hakeem M; Khalil O; Maklad Y
    Bioorg Med Chem; 2008 Jan; 16(1):382-9. PubMed ID: 17905589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cardiac phosphodiesterase III by the novel cardiotonic agent 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride.
    Sellin LC; Alajoutsijärvi A; Törnquist K; Fraser M; Pippuri A; Ojala I
    Arzneimittelforschung; 1988 Dec; 38(12):1787-9. PubMed ID: 2854467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesterase.
    Stafford JA; Veal JM; Feldman PL; Valvano NL; Baer PG; Brackeen MF; Brawley ES; Connolly KM; Domanico PL; Han B
    J Med Chem; 1995 Dec; 38(26):4972-5. PubMed ID: 8544172
    [No Abstract]   [Full Text] [Related]  

  • 17. Mesoionic purinone analogues as inhibitors of cyclic-AMP phosphodiesterase: a comparison of several ring systems.
    Rogers ME; Glennon RA; Smith JD; Boots MR; Nanavati N; Maconaughey E; Aub D; Thomas S; Bass RG; Mbagwu G
    J Med Chem; 1981 Nov; 24(11):1284-7. PubMed ID: 6273558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
    Dal Piaz V; Giovannoni MP; Castellana C; Palacios JM; Beleta J; Doménech T; Segarra V
    J Med Chem; 1997 May; 40(10):1417-21. PubMed ID: 9154964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents.
    Hagedorn AA; Erhardt PW; Lumma WC; Wohl RA; Cantor E; Chou YL; Ingebretsen WR; Lampe JW; Pang D; Pease CA
    J Med Chem; 1987 Aug; 30(8):1342-7. PubMed ID: 3039132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phthalazine PDE IV inhibitors: conformational study of some 6-methoxy-1,4-disubstituted derivatives.
    Haack T; Fattori R; Napoletano M; Pellacini F; Fronza G; Raffaini G; Ganazzoli F
    Bioorg Med Chem; 2005 Jul; 13(14):4425-33. PubMed ID: 15927474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.